NEW YORK, NY / ACCESS Newswire / January 21, 2025 / If you suffered a loss on your BioAge Labs, Inc. (NASDAQ:BIOA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bioage-labs-inc-lawsuit-submission-form?prid=124225&wire=1 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or […]

NEW YORK, NY / ACCESS Newswire / January 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Atara Biotherapeutics, Inc. ("Atara Biotherapeutics, Inc.") (NASDAQ:ATRA) concerning possible violations of federal securities laws. Atara issued a press release on January 16, 2025, announcing receipt of "a Complete Response Letter (CRL) from

NEW YORK, NY / ACCESS Newswire / January 21, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Caribou Biosciences, Inc. (NASDAQ:CRBU) between July 14, 2023 and July 16, 2024, both dates inclusive (the "Class Period"), of the important February 24, 2025 lead plaintiff deadline. SO WHAT:

NEW YORK, NY / ACCESS Newswire / January 21, 2025 / Rosen Law Firm PA WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Shares ("ADS") of Rentokil Initial plc (NYSE:RTO) between December 1, 2023 and September 10, 2024, both dates inclusive (the "Class Period"), of the important January

Pomerantz LLP announces that a class action lawsuit has been filed against Applied Therapeutics, Inc. (“Applied Therapeutics” or the “Company”)(NASDAQ: APLT).Such investors are advised to contact Danielle Peyton at newaction@pomlaw.comor 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares

(NasdaqGM:AVBP),(HKSE:02157.HK),(HKSE:02157), Exclusive global license outside of Greater China for MRG007, a novel antibody drug conjugate (ADC) in development for gastrointestinal (GI) cancers First Investigational New Drug (IND) submission planned for 1H 2025 Expands ArriVent's growing pipeline of next-generation ADCs NEWTOWN SQUARE, Pa. and SHANGHAI, Jan. 21, 2025 (GLOBE NEWSWIRE) — ArriVent BioPharma, Inc. (Company or

Pomerantz LLP announces that a class action lawsuit has been filed against Joint Stock Company Kaspi.kz (“Kaspi.kz” or the “Company”)(NASDAQ: KSPI). Such investors are advised to contact DaniellePeyton at newaction@pomlaw.comor 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares

H2, Inc., an industry-leading vanadium flow battery (VFB) developer and manufacturer headquartered in South Korea, successfully raised $16 million in recent bridge funding, finalized in the second half of 2024. This brings the company's total accumulated funding to $77 million. The round was led by STIC Investments which is one of the largest and a

With ITG's Storyteq technology having been named a Leader in the Gartner® Magic Quadrant™ for both Content Marketing Platforms and Digital Asset Management, David Mackay's appointment capitalizes on the company's momentum to bring ITG's AI-enabled content solutions to more US marketers. Inspired Thinking Group (ITG), the tech-enabled, agile content business, has today announced the appointment

Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC (“AstraZeneca” or the “Company”)(NASDAQ: AZN).Such investors are advised to contact Danielle Peyton at newaction@pomlaw.comor 646-581-9980, ext.7980. https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg The investigation concerns whether AstraZeneca and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information